Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:27 2024-06-21 EDT 5-day change 1st Jan Change
334 GBX +1.46% Intraday chart for Haleon plc +2.99% +3.84%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Factbox-European companies cut jobs as economy sputters RE
Certain Ordinary Shares of Haleon plc are subject to a Lock-Up Agreement Ending on 18-JUN-2024. CI
Certain American Depositary Shares of Haleon plc are subject to a Lock-Up Agreement Ending on 18-JUN-2024. CI
Haleon: share price rises, Berenberg initiates buy decision CF
Transcript : Haleon plc Presents at 21st Annual dbAccess Global Consumer Conference 2024, Jun-05-2024 04:30 PM
Berenberg Initiates Haleon Coverage at Buy MT
HALEON : Berenberg initiates buy coverage CF
Berenberg raises Taylor Wimpey to 'buy' AN
Delaware judge lets more than 70,000 Zantac lawsuits go forward RE
Suave Brands Company LLC acquired ChapStick Brand of Haleon plc. CI
Bernstein becomes more optimistic for consumer goods - Henkel upgraded DP
UK's FTSE 100 Closes Lower Amid Inflation Focus MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion MT
FTSE 100 slides; Eurozone inflation steady AN
London stocks dip as global rates outlook weighs RE
GSK sells remaining Haleon stake for GBP1.25 billion AN
FTSE 100 lacklustre as Wall Street rally ends AN
London stocks lacklustre but set for weekly gains RE
Land Securities ups dividend; GSK sells Haleon stake AN
GSK Divests Remaining Haleon Stake in GBP1.25 Billion Deal MT
GSK Sells Last Haleon Shares for $1.58 Billion DJ
GSK raises $1.5 bln from sale of remaining Haleon stake RE
GSK Raises About 1.25 Bln Stg Via Haleon Stake Sale RE
GSK to Sell Remaining Haleon Stake MT
An unknown buyer completed the acquisition of 4.2% stake in Haleon plc from GSK plc for £1.2 billion. CI
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.34 GBP
Average target price
3.646 GBP
Spread / Average Target
+9.18%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. British Healthcare Company Haleon Names Tate & Lyle CFO as New Finance Chief